Necdin and E2F4 are modulated by rosiglitazone therapy in diabetic human adipose and muscle tissue

Diabetes

Volumn 55, Issue 3, 2006, Pages 640-650

  Goldfine, Allison B ^a,b   Crunkhorn, Sarah ^a   Costello, Maura ^a   Gami, Hiral ^a   Landaker, Edwin J ^a   Niinobe, Michio ^c   Yoshikawa, Kazuaki ^c   Lo, David ^d,e   Warren, Amy ^d   Jimenez Chillaron, Jose ^a   Patti, Mary Elizabeth ^a,b  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c OSAKA UNIVERSITY   (Japan)

^d Digital Gene Technologies Inc   (United States)

^e LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; COMPLEMENTARY DNA; MELANOMA ANTIGEN; MESSENGER RNA; NECDIN; ROSIGLITAZONE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F4;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ADULT; ANIMAL CELL; ANIMAL MODEL; ARTICLE; AUTOANALYSIS; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL LINE; CONTROLLED STUDY; CYTOSOL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INSULIN SENSITIVITY; MALE; MOUSE; MUSCLE TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FOLDING; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; RESTRICTION MAPPING;

EID: 33644777808     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/diabetes.55.03.06.db05-1015     Document Type: Article

References (50)

1. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649-688, 1999
2. Shulman GI, Rothman DL, Jue R, Stein P, DeFronzo RA, Shulman RG: Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 322:223-228, 1990
3. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
4. Spiegelman BM: PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514, 1998
5. Shibasaki M, Takahashi K, Itou T, Bujo H, Saito Y: A PPAR agonist improves TNF-alpha-induced insulin resistance of adipose tissue in mice. Biochem Biophys Res Commun 309:419-424, 2003
6. Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM, Kahn CR: Musclespecific PPAR-gamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 112:608-618, 2003
7. Tordjman J, Chauvet G, Quette J, Beale EG, Forest C, Antoine B: Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells. J Biol Chem 278:18785-18790, 2003
8. Wilmsen HM, Ciaraldi TP, Carter L, Reehman N, Mudaliar SR, Henry RR: Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am J Physiol 285:E354-E362, 2003
9. Boden G, Cheung P, Mozzoli M, Fried SK: Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism 52:753-759, 2003
10. Tamori Y, Masugi J, Nishino N, Kasuga M: Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 51:2045-2055, 2002
11. Auwerx J: PPAR-gamma, the ultimate thrifty gene. Diabetologia 42:1033-1049, 1999
12. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA: Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 61:6213-6218, 2001
13. Kim KA, Park JY: Simple and extractionless high-performance liquid chromatographic determination of rosiglitazone in human plasma and application to pharmacokinetics in humans. Biomed Chromatogr 18:613-615, 2004
14. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI: Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86:280-288, 2001
15. Patel J, Anderson RJ, Rappaport EB: Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1:165-172, 1999
16. Sutcliffe JG, Foye PE, Erlander MG, Hilbush BS, Bodzin LJ, Durham JT, Hasel KW: TOGA: an automated parsing technology for analyzing expression of nearly all genes. Proc Natl Acad Sci U S A 97:1976-1981, 2000
17. Klein D: Quantification using real-time PCR technology: applications and limitations. Trends in Mol Med 8:257-260, 2003
18. Niinobe M, Koyama K, Yoshikawa K: Cellular and subcellular localization of necdin in fetal and adult mouse brain. Dev Neurosci 22:310-319, 2000
19. Muller H, Moroni MC, Vigo E, Petersen BO, Bartek J, Helin K: Induction of S-phase entry by E2F transcription factors depends on their nuclear localization. Mol Cell Biol 17:5508-5520, 1997
20. Hayashi Y, Matsuyama K, Takagi K, Sugiura H, Yoshikawa K: Arrest of cell growth by necdin, a nuclear protein expressed in postmitotic neurons. Biochem Biophys Res Commun 213:317-324 1995
21. Kobayashi M, Taniura H, Yoshikawa K: Ectopic expression of necdin induces differentiation of mouse neuroblastoma cells. J Biol Chem 277:42128-42135, 2002
22. Fajas L, Landsberg RL, Huss-Garcia Y, Sardet C, Lees JA, Auwerx J: E2Fs regulate adipocyte differentiation. Dev Cell 3:39-49, 2002
23. Tseng Y-H, Butte AJ, Kokkotou E, Yechoor VK, Taniguchi CM, Kriauciunas KM, Niinobe M, Yoshikawa K, Patti ME, Kahn CR: Prediction of preadipocyte differentiation by gene expression reveals role of insulin receptor substrates and necdin. Nat Cell Biol 7:601-611, 2005
24. Boney CM, Fiedorek FT Jr, Paul SR, Grupposo PA: Regulation of preadipocyte factor-1 gene expression during 3T3-L1 cell differentiation. Endocrinology 137:2923-2928, 1996
25. Riserus U, Tan GD, Fielding BA, Neville MJ, Currie J, Savage DB, Chatterjee VK, Frayn KN, O'Rahilly S, Karpe F: Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-γ. Diabetes 54:1379-1384, 2005
26. Karlsson HK, Hallsten K, Bjornholm M, Tsuchida H, Chibalin AV, Virtanen KA, Heinonen OJ, Lonnqvist F, Nuutila P, Zierath JR: Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study. Diabetes 54:1459-1467, 2005
27. Hammarstedt A, Sopasakis VR, Gogg S, Jansson PA, Smith U: Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia 48:96-104, 2005
28. Gerhold DL, Liu F, Jiang G, Li Z, Xu J, Lu M, Sachs JR, Bagchi A, Fridman A, Holder DJ, Doebber TW, Berger J, Elbrecht A, Moller DE, Zhang BB: Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists. Endocrinology 143:2106-2118, 2002
29. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, Mansfield TA, Ramachandran RK, Willson TM, Kliewer SA: Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferatoractivated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142:1269-1277, 2001
30. Slansky JE, Farnham PJ: Introduction to the E2F family: protein structure and gene regulation. Curr Top Microbiol Immunol 208:1-30, 1996
31. Dyson N: The regulation of E2F by pRB-family proteins. Genes Dev 12:2245-2262, 1998
32. Mulligan G, Jacks T: The retinoblastoma gene family: cousins with overlapping interests. Trends Genet 14:223-229, 1998
33. Trimarchi JM, Lees JA: Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 3:11-20, 2002
34. Landsberg RL, Sero JE, Danielian PS, Yuan TL, Lee EY, Lees JA: The role of E2F4 in adipogenesis is independent of its cell cycle regulatory activity. Proc Natl Acad Sci U S A 100:2456-2461, 2003
35. Barker PA, Salehi A: The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res 67:705-712, 2002
36. Sasaki M, Nakahira K, Kawano Y, Katakura H, Yoshimine T, Shimizu K, Kim SU, Ikenaka K: MAGE-E1, a new member of the melanoma-associated antigen gene family and its expression in human glioma. Cancer Res 61:4809-4814, 2001
37. Maruyama K, Usami M, Aizawa T, Yoshikawa K: A novel brain-specific mRNA encoding nuclear protein (necdin) expressed in neurally differentiated embryonal carcinoma cells. Biochem Biophys Res Commun 178:291-296, 1991
38. Taniguchi N, Taniura H, Niinobe M, Takayama C, Tominaga-Yoshino K, Ogura A, Yoshikawa K: The postmitotic growth suppressor necdin interacts with a calcium-binding protein (NEFA) in neuronal cytoplasm. J Biol Chem 275:31674-31681, 2000
39. Boeuf S, Klingenspor M, Van Hal NL, Schneider T, Keijer J, Klaus S: Differential gene expression in white and brown preadipocytes. Physiol Genomics 7:15-25, 2001
40. Jay P, Rougeulle C, Massacrier A, Moncla A, Mattei MG, Malzac P, Roeckel N, Taviaux S, Lefranc JL, Cau P, Berta P, Lalande M, Muscatelli F: The human necdin gene, NDN, is maternally imprinted and located in the Prader-Willi syndrome chromosomal region. Nat Genet 17:357-361, 1997
41. Cassidy SB: Prader-Willi syndrome. J Med Genet 34:917-923, 1997
42. Hoybye C, Hilding A, Jacobsson H, Thoren M: Metabolic profile and body composition in adults with Prader-Willi syndrome and severe obesity. J Clin Endocrinol Metab 87:3590-3597, 2002
43. Yang T, Adamson TE, Resnick JL, Leff S, Wevrick R, Francke U, Jenkins NA, Copeland NG, Brannan CI: A mouse model for Prader-Willi syndrome imprinting-centre mutations. Nat Genet 19:25-31, 1998
44. Gerard M, Hernandez L, Wevrick R, Stewart CL: Disruption of the mouse necdin gene results in early post-natal lethality. Nat Genet 23:199-202, 1999
45. Muscatelli F, Abrous DN, Massacrier A, Boccaccio I, Le Moal M, Cau P, Cremer H: Disruption of the mouse Necdin gene results in hypothalamic and behavioral alterations reminiscent of the human Prader-Willi syndrome. Hum Mol Genet 9:3101-3110, 2000
46. Oeffner F, Korn T, Roth H, Ziegler A, Hinney A, Goldschmidt H, Siegfried W, Hebebrand J, Grzeschik KH: Systematic screening for mutations in the human necdin gene (NDN): identification of two naturally occurring polymorphisms and association analysis in body weight regulation. Int J Obes Relat Metab Disord 25:767-769, 2001
47. Taniura H, Taniguchi N, Hara M, Yoshikawa K: Necdin, a postmitotic neuron-specific growth suppressor interacts with viral transforming proteins and cellular transcription factor E2F1. J Biol Chem 273:720-728, 1998
48. Rangwala SM, Lazar MA: Transcriptional control of adipogenesis. Annu Rev Nutr 20:535-559, 2000
49. Chen PL, Riley DJ, Chen Y, Lee WH: Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. Genes Dev 10:2794-2804, 1996
50. Matsumoto K, Taniura H, Uetsuki T, Yoshikawa K: Necdin acts as a transcriptional repressor that interacts with multiple guanosine clusters. Gene 272:173-179, 2001